| Ticker: BCORY | ||
| Exchange: NASDAQ-National Market | Uppsala, Foreign | |
| Industry: Manufacturing |
| Type of Shares: | American Depositary Receipts | Filing Date: | 11/8/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 11/26/96 | |
| Non-U.S. Shares: | 2,000,000 | Filing Range: | $15.00 - $17.00 | |
| Primary Shares: | 1,500,000 | Offer Price: | $16.00 | |
| Secondary Shares: | 3,500,000 | Gross Spread: | $1.12 | |
| Offering Amount: | $80,000,000 | Selling: | $0.61 | |
| Expenses: | $2,555,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,750,000 |
| Manager | Tier | Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-1172 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 9/30/96 | 9/30/96 | |||
| Revenue: | $31.52 | $27.91 | Assets: | $26.75 | |
| Net Income: | $5.44 | $5.63 | Liabilities: | $19.13 | |
| EPS: | $0.56 | $0.58 | Equity: | $7.62 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is the global leader in developing, manufacturing and marketing advanced scientific instruments that employ affinity-based biosensor technology. The company pioneered the development of this technology, which is used for determining the function and concentration of biomolecules ( substances related to biological processes). Since the company's first system was commercially introduced in 1990, the company has carried on an intensive campaign through scientific symposia and marketing activities to promote its technology within the academic and commercial research communities. Today, the company's technology is an established tool for life science research, and the company supplies its BIACORE systems across Europe, North America, japan and elsewhere in Asia Pacific, primarily to scientific research laboratories of academic institutes, government agencies and the pharmaceutical, biotechnology and diagnostic industries. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for general corporate purposes including capital expenditures associated with the expansion of the company's business and possible acquisitions. |
©1996 IPO Data Systems, Inc. - All rights reserved.